5Y News | Xuanming Life Sciences Closes Tens of Millions of Dollars in Series A Funding
Accelerating the intelligent design of antibodies and the development of innovative pipelines.
Aureka Biotechnologies, a biotech company focused on generative antibody drug development, recently announced the completion of a tens-of-millions-of-dollars Series A funding round. The round was co-led by 5Y Capital and Qiming Venture Partners, with continued investment from existing shareholder New Alliance Capital and follow-on investment from Agentic Ventures and other institutions.
The proceeds will be used to advance the company's innovative pipeline into critical clinical stages, accelerate the development of its wet-dry closed-loop antibody design agent platform, and expand deep partnerships with global biopharmaceutical companies.
Xutian Jing, Partner at 5Y Capital, said: "Aureka's ultra-high-throughput antigen-antibody data generation platform is a powerful complement to today's algorithm-driven large-molecule drug R&D models, offering strong scarcity value. We look forward to seeing the company bring more high-value clinical assets to the antibody drug space through entirely new tools and methodologies."
Aureka Biotechnologies is an innovative biotech company dedicated to generative antibody drug development. The company has built a data-driven, wet-dry closed-loop intelligent large-molecule drug discovery platform by combining high-throughput single-cell functional screening, an intracellular yeast automated directed evolution platform, and structure-inspired autonomous evolutionary antibody design agents. By fundamentally transforming the paradigm of functional data generation, Aureka creates a high-throughput, high-content experimental data flywheel for its agents, enabling differentiated antibody discovery and optimization capabilities to efficiently develop First-in-Class and Best-in-Class antibody drug pipelines. In just over two years since its founding, the company has successfully delivered projects for multiple MNCs, securing over ten million dollars in orders.
Reconstructing the Paradigm of Antibody Drug Design with a Wet-Dry Closed-Loop Agent Platform
Aureka builds autonomous evolutionary antibody design agents, integrating them with high-throughput single-cell functional screening and intracellular yeast automated directed evolution platforms to fundamentally transform how functional data is generated. This creates a high-throughput, high-content experimental data flywheel for its agents, enabling differentiated antibody discovery and optimization capabilities to efficiently develop First-in-Class and Best-in-Class antibody drug pipelines.
The company continuously optimizes the functional dimensions, phenotypic precision, and throughput of its data acquisition, constructing antibody design agents capable of handling multi-dimensional, multi-objective tasks that iterate autonomously. This steadily expands the models' generalization boundaries and directed optimization capabilities across complex targets, mechanisms, and indications. Aureka has made targeted deployments in multiple high-value, high-challenge domains including epitope-specific targeting antibodies, multispecific antibodies, endocytic antibodies, and pH-switch antibodies—ensuring that agent-designed molecules achieve greater safety, superior efficacy, and ultimately better therapeutic effects with differentiated clinical advantages.
Advancing Technology Validation and Commercial Translation in Parallel
On technology validation and commercial partnerships, Aureka has established substantive collaborations with multiple large European and American pharmaceutical companies, launching joint projects around complex targets and functional mechanisms that have demonstrated the platform's substantial advantages over traditional platforms in these high-value application scenarios.
Meanwhile, the company is advancing multiple proprietary pipelines, with a strategic focus on autoimmune and metabolic diseases—therapeutic areas with significant unmet medical need. Several programs have already reached critical PCC or pre-IND stages.
Over the past two years, Aureka has achieved tens of millions of dollars in commercial revenue and continues to expand medium- to long-term pipeline co-development and joint development opportunities.
Dr. Weian Zhao, Founder and CEO of Aureka Biotechnologies, said: "We believe antibody drugs are not merely to be 'discovered'—they can be designed. Truly unlocking the potential of autonomous agents lies not in auxiliary analysis, but in enabling them to participate in decision-making, drive design, and guide experiments, achieving iterative closed loops through high-throughput experimental platforms. What we aim to build is not merely an algorithmic model, but a continuously evolving world model of antibody design with active creative capacity."
5Y Capital seeks out, supports, and inspires lonely entrepreneurs, providing support from the spiritual to the operational. We believe that if the "crazy" you in others' eyes begins to be believed in, the world will become a different place.
BEIJING · SHANGHAI · SHENZHEN · HONG KONG